ReviewAsian Pacific journal of cancer prevention : APJCP2025
Understanding the Role of Rho GTPase Activating Protein and Bone Marrow Kinase X: A Novel Target in Gastric Cancer Treatment.
Review in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the role of Rho GTPase Activating Protein (ARHGAP) and Bone Marrow Kinase X (BMX) in the progression and development of gastric cancer (GC), and to highlight their potential as therapeutic targets.
methodA comprehensive literature review was conducted to assess current evidence regarding the involvement of ARHGAP and BMX in GC, focusing on their expression levels, association with prognosis, and impact on tumor behavior.
resultsCurrent research indicates that both ARHGAP and BMX are up-regulated in GC tissues, correlating with poor prognosis and aggressive tumor characteristics. These findings suggest that they play significant roles in the mechanisms underlying GC progression.
conclusionThe evidence supports the critical involvement of ARHGAP and BMX in GC, suggesting their potential as therapeutic targets. Further research is essential to clarify the mechanisms by which these proteins influence gastric cancer progression and to evaluate their viability as targets for new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.